Showing results (51-60 of 84) with videos related to
Sort By:
Pageof 9
Journal for Immunotherapy of Cancer|November 23, 2019
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancerLorenza Landi, Federica D'Incà, Alain Gelibter, et al.Cancers|July 12, 2025
TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-AnalysisLeonardo Brunetti, Valentina Santo, Alessandro Galletti, et al.Vaccines|May 2, 2020
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with ImmunotherapyAndrea Botticelli, Alessio Cirillo, Simone Scagnoli, et al.Journal of Translational Medicine|November 16, 2019
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practiceAlessio Cortellini, Maria G Vitale, Federica De Galitiis, et al.Journal for Immunotherapy of Cancer|August 8, 2020
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genesMarco Mazzotta, Marco Filetti, Mario Occhipinti, et al.Advances in Therapy|February 1, 2020
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter StudyAlessandro Russo, Marco Russano, Tindara Franchina, et al.Lung Cancer (Amsterdam, Netherlands)|December 30, 2019
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patientsMaria Lucia Reale, Rita Chiari, Marcello Tiseo, et al.Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.Expert Opinion on Biological Therapy|February 4, 2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabFrancesco Pantano, Marco Russano, Alfredo Berruti, et al.European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.Pageof 9